\BOOKMARK [0][-]{Doc-Start}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.1}{Acknowledgement}{}% 2
\BOOKMARK [0][-]{chapter*.5}{Symbols and Acronyms}{}% 3
\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 4
\BOOKMARK [0][-]{chapter.2}{Background Study}{}% 5
\BOOKMARK [0][-]{chapter.3}{Drug Repurposing}{}% 6
\BOOKMARK [1][-]{section.3.1}{Background}{chapter.3}% 7
\BOOKMARK [2][-]{subsection.3.1.1}{Motivation}{section.3.1}% 8
\BOOKMARK [2][-]{subsection.3.1.2}{Related Works}{section.3.1}% 9
\BOOKMARK [2][-]{subsection.3.1.3}{Significances}{section.3.1}% 10
\BOOKMARK [1][-]{section.3.2}{Datasets and Methods}{chapter.3}% 11
\BOOKMARK [2][-]{subsection.3.2.1}{Datasets}{section.3.2}% 12
\BOOKMARK [2][-]{subsection.3.2.2}{Methods}{section.3.2}% 13
\BOOKMARK [1][-]{section.3.3}{Experiment Results}{chapter.3}% 14
\BOOKMARK [2][-]{subsection.3.3.1}{Predictive performance comparison}{section.3.3}% 15
\BOOKMARK [2][-]{subsection.3.3.2}{Enrichment for psychiatric drugs considered clinical trials}{section.3.3}% 16
\BOOKMARK [2][-]{subsection.3.3.3}{Correlation of predicted probabilities with degree of literature support}{section.3.3}% 17
\BOOKMARK [2][-]{subsection.3.3.4}{Identifying contributing genes and pathways}{section.3.3}% 18
\BOOKMARK [2][-]{subsection.3.3.5}{Top repositioning hits and literature support from previous studies}{section.3.3}% 19
\BOOKMARK [1][-]{section.3.4}{Discussion}{chapter.3}% 20
\BOOKMARK [1][-]{section.3.5}{Conclusion}{chapter.3}% 21
\BOOKMARK [0][-]{chapter.4}{Drug Target Discovery}{}% 22
\BOOKMARK [1][-]{section.4.1}{Introduction}{chapter.4}% 23
\BOOKMARK [2][-]{subsection.4.1.1}{Motivation}{section.4.1}% 24
\BOOKMARK [2][-]{subsection.4.1.2}{Related Works}{section.4.1}% 25
\BOOKMARK [1][-]{section.4.2}{Datasets and Methods}{chapter.4}% 26
\BOOKMARK [2][-]{subsection.4.2.1}{Datasets}{section.4.2}% 27
\BOOKMARK [2][-]{subsection.4.2.2}{Methods}{section.4.2}% 28
\BOOKMARK [1][-]{section.4.3}{Experiment Results}{chapter.4}% 29
\BOOKMARK [2][-]{subsection.4.3.1}{Model Performance}{section.4.3}% 30
\BOOKMARK [2][-]{subsection.4.3.2}{External Validation}{section.4.3}% 31
\BOOKMARK [2][-]{subsection.4.3.3}{Literature Support}{section.4.3}% 32
\BOOKMARK [1][-]{section.4.4}{Discussion}{chapter.4}% 33
\BOOKMARK [1][-]{section.4.5}{Conclusion}{chapter.4}% 34
\BOOKMARK [0][-]{chapter.5}{Evaluating Individualized Treatment Effects \(ITE\) of Genetic Risk Factors on Patient Outcomes}{}% 35
\BOOKMARK [1][-]{section.5.1}{Motivation}{chapter.5}% 36
\BOOKMARK [1][-]{section.5.2}{Background}{chapter.5}% 37
\BOOKMARK [1][-]{section.5.3}{Overview of Related Work}{chapter.5}% 38
\BOOKMARK [2][-]{subsection.5.3.1}{Background Methods}{section.5.3}% 39
\BOOKMARK [2][-]{subsection.5.3.2}{Causal Forests}{section.5.3}% 40
\BOOKMARK [1][-]{section.5.4}{ITE Framework}{chapter.5}% 41
\BOOKMARK [2][-]{subsection.5.4.1}{Novel Tests for the presence of heterogeneity}{section.5.4}% 42
\BOOKMARK [2][-]{subsection.5.4.2}{Modeling Survival Outcomes}{section.5.4}% 43
\BOOKMARK [1][-]{section.5.5}{Experiment Results}{chapter.5}% 44
\BOOKMARK [2][-]{subsection.5.5.1}{Simulations Studies}{section.5.5}% 45
\BOOKMARK [2][-]{subsection.5.5.2}{Applications on Real Data}{section.5.5}% 46
\BOOKMARK [1][-]{section.5.6}{Conclusion}{chapter.5}% 47
\BOOKMARK [0][-]{chapter.6}{Conclusion}{}% 48
\BOOKMARK [0][-]{appendix.A}{Proof of Propositions}{}% 49
\BOOKMARK [0][-]{appendix.B}{Publication List}{}% 50
\BOOKMARK [0][-]{appendix.B}{Bibliography}{}% 51
